Effects of Low-Dose Spironolactone Combined with Metformin or Either Drug Alone on Insulin Resistance in Patients with Polycystic Ovary Syndrome: A Pilot Study
March 2022
in “
International Journal of Endocrinology
”
Studysummary This study found that combining low-dose spironolactone with metformin improved insulin resistance in PCOS patients more effectively than using either drug alone.
Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer
This pilot study examined the effects of low-dose spironolactone combined with metformin, compared to each drug alone, on insulin resistance in 158 patients with polycystic ovary syndrome (PCOS). Participants were divided into three groups: metformin, spironolactone, and combination therapy. After 12 weeks, the combination therapy was more effective in reducing insulin resistance, as indicated by greater reductions in HOMA-IR, total testosterone, and free androgen index, compared to either drug alone. The study concluded that the combined use of spironolactone and metformin improved insulin resistance and related metabolic and hormonal profiles in PCOS patients more effectively than monotherapy. No significant changes in hirsutism scores were observed, and the safety profile was similar across all groups. Further research was suggested due to study limitations such as short follow-up duration.
